

22 August 2023

**Our Ref:** RFI 52723

Dear

**Freedom of Information Act 2000  
Information in Relation to the Usage of Ruxolitinib**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 09 August 2023.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care & Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Robyn Watterson**  
**Information Governance Officer**

**Q1. Could you please tell me how many patients your Trust has treated in the past 6 months (for any disease) with the following:**

- ***Ruxolitinib – any strength***
- ***Ruxolitinib – 5mg tablets***
- ***Ruxolitinib – 10mg tablets***

A1. Please see the table below.

<b>Medication</b>	<b>Number of Patients</b>
Ruxolitinib – any strength	8
Ruxolitinib – 5mg tablets	<5
Ruxolitinib – 10mg tablets	<5

**Q2. In case you are able to link Ruxolitinib usage to disease, could you also provide the number of patients treated in the last 6 months for myelofibrosis ONLY with**

- ***Ruxolitinib – any strength***
- ***Ruxolitinib – 5mg tablets***
- ***Ruxolitinib – 10mg tablets***

A2. All the patients listed in the table above who are receiving Ruxolitinib have a diagnosis of Myelofibrosis.